Kalamazoo, Michigan headquartered Stryker Corp.'s stock edged 0.56% higher, to close the day at $120.10. The stock recorded a trading volume of 1.50 million shares, which was above its three months average volume of 1.46 million shares. Stryker's shares have gained 7.53% in the last one month, 3.67% in the previous three months and 33.96% in the past one year. The Company's shares are trading 4.68% and 5.94% above its 50-day and 200-day moving averages, respectively. Shares of the Company, which together with its subsidiaries, operates as a medical technology company, are trading at a PE ratio of 27.38. Additionally, the stock has a Relative Strength Index (RSI) of 60.90. Visit us today and download your complete report on SYK for free at:
On Wednesday, shares in Richmond, Canada headquartered Neovasc Inc. ended the session 8.05% higher at $1.88 with a total volume of 2.38 million shares traded. Neovasc's shares have rallied 118.60% in the last one month and 270.08% in the previous three months. The stock is trading 70.12% above its 50-day moving average and 44.59% above its 200-day moving average. Moreover, shares of the Company, develops, manufactures, and markets cardiovascular products worldwide, have an RSI of 59.60. The complimentary research report on NVCN can be accessed at:
On Wednesday, shares in Salt Lake City, Utah headquartered Amedica Corp. recorded a trading volume of 184,103 shares. The stock ended the day 0.14% higher at $0.65. Amedica's stock has advanced 1.25% in the last one month. The Company is trading below its 50-day and 200-day moving averages by 8.26% and 38.32%, respectively. Furthermore, shares of Amedica, which develops, manufactures, and sells a range of medical devices based on its silicon nitride ceramic technology platform in the US, Europe, and South America, have an RSI of 49.89. Register for free on Stock-Callers.com and download the PDF research report on AMDA at:
San Diego, California headquartered ResMed Inc.'s stock finished Wednesday's session 0.65% higher at $62.35 with a total volume of 759,493 shares traded. Over the last one month and the previous one year, ResMed's shares have gained 4.75% and 21.40%, respectively. The Company's shares are trading above its 50-day and 200-day moving averages by 3.35% and 1.33%, respectively. Shares of ResMed, which designs, develops, manufactures, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders, are trading at a PE ratio of 25.36. The stock has an RSI of 60.83. Get free access to your research report on RMD at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA